News & Updates
Filter by Specialty:

HCC incidence rare in autoimmune hepatitis, tied to obesity, cirrhosis
The incidence of hepatocellular carcinoma (HCC) remains low in patients with autoimmune hepatitis (AIH) even after developing cirrhosis, according to a study. Factors such as obesity, cirrhosis, and AIH/primary sclerosing cholangitis (PSC) variant syndrome can increase the risk of HCC incidence.
HCC incidence rare in autoimmune hepatitis, tied to obesity, cirrhosis
19 Jan 2024
GLP-1RA users face no elevated risk of pancreatic cancer
Among individuals with type 2 diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) does not contribute to increased pancreatic cancer risk, according to a study.
GLP-1RA users face no elevated risk of pancreatic cancer
16 Jan 2024
Can SLN mapping replace lymphadenectomy for surgical staging of early-stage EEC?
Researchers from the KK Women’s and Children’s Hospital, Singapore found that sentinel lymph node (SLN) mapping is an acceptable and safe alternative to routine lymphadenectomy in the surgical staging of early-stage endometrioid endometrial cancer (EEC).
Can SLN mapping replace lymphadenectomy for surgical staging of early-stage EEC?
15 Jan 2024
Antivirals underutilized after curative resection of HBV- or HCV-related HCC
Antiviral therapy is associated with substantial improvements in long-term overall survival (OS) but severely underutilized after curative hepatic resection in patients with hepatitis B virus (HBV)– or hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC), a real-world study involving predominantly Asian patients has shown.
Antivirals underutilized after curative resection of HBV- or HCV-related HCC
15 Jan 2024
Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC
The next-generation ROS1 and TRK tyrosine kinase inhibitor (TKI) repotrectinib has demonstrated high response rates and durable activity in patients with ROS1 fusion–positive non-small-cell lung cancer (NSCLC), regardless of whether they have previously received ROS1 TKI therapy, according to phase II results of the ongoing registrational TRIDENT-1 trial.
Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC
15 Jan 2024
Resection plus chemo improves survival in patients with UCR-MAC-LM
Primary tumour resection (PTR) in combination with chemotherapy (C) appears beneficial to a specific subgroup of patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM) compared with PTR or C alone, suggests a study.